Analysis of outcomes in resected early-stage non-small cell lung cancer (NSCLC) with rare targetable driver mutations. Neoadjuvant hypofractionated radiotherapy combined with pembrolizumab plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback